841 related articles for article (PubMed ID: 11888582)
1. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
[TBL] [Abstract][Full Text] [Related]
2. [HLA-B*5701 and abacavir hypersensitivity reaction].
Servonnet A; Leclercq E; Delacour H; Ceppa F
Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
[TBL] [Abstract][Full Text] [Related]
3. Current trends in screening across ethnicities for hypersensitivity to abacavir.
Rodriguez-Nóvoa S; Soriano V
Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
[TBL] [Abstract][Full Text] [Related]
4. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
5. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.
Martin AM; Nolan D; Gaudieri S; Almeida CA; Nolan R; James I; Carvalho F; Phillips E; Christiansen FT; Purcell AW; McCluskey J; Mallal S
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4180-5. PubMed ID: 15024131
[TBL] [Abstract][Full Text] [Related]
6. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
[TBL] [Abstract][Full Text] [Related]
7. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
8. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
[TBL] [Abstract][Full Text] [Related]
9. High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.
Siljic M; Salemovic D; Cirkovic V; Pesic-Pavlovic I; Todorovic M; Ranin J; Dragovic G; Jevtovic D; Stanojevic M
Intervirology; 2017; 60(1-2):43-47. PubMed ID: 28772259
[TBL] [Abstract][Full Text] [Related]
10. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T
Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404
[TBL] [Abstract][Full Text] [Related]
11. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M
Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
[TBL] [Abstract][Full Text] [Related]
14. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.
Sanchez-Giron F; Villegas-Torres B; Jaramillo-Villafuerte K; Silva-Zolezzi I; Fernandez-Lopez JC; Jimenez-Sanchez G; Carnevale A
Pharmacogenomics; 2011 Jun; 12(6):809-14. PubMed ID: 21510768
[TBL] [Abstract][Full Text] [Related]
15. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
[TBL] [Abstract][Full Text] [Related]
16. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
17. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
Small CB; Margolis DA; Shaefer MS; Ross LL
BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
[TBL] [Abstract][Full Text] [Related]
18. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
[TBL] [Abstract][Full Text] [Related]
19. Cytokine profiling in abacavir hypersensitivity patients.
Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
[TBL] [Abstract][Full Text] [Related]
20. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
